S-1: Biotricity S-1: Cardiac Monitoring Growth Amidst Financial Strain

Biotricity Inc. files S-1, detailing expansion in cardiac monitoring solutions and AI development, alongside significant financial challenges including recurring losses and going concern doubt.

Summary

• Biotricity Inc. is a medical technology company focused on biometric data monitoring solutions, particularly for diagnostic and post-diagnostic cardiac care.
• The company has developed an ecosystem of technologies including Bioflux (FDA-cleared COM technology), Bioheart (direct-to-consumer heart monitor), Biotres/Biocore (three-lead ECG and arrhythmia monitoring device), and Biocare (Cardiac Disease Management Solution).
• Sales efforts have expanded to 33 U.S. states by December 31, 2023, with intentions for further expansion in the broader U.S. market and international distribution.
• Biotricity focuses on a utilization-based recurring technology fee revenue model, aiming for efficient market penetration and reduced operating overhead.
• The company received a NIH Grant of $238,703 in March 2023 for AI-enabled real-time monitoring and predictive analytics for stroke due to chronic kidney failure.
• Biotricity has monitored over two billion heartbeats for atrial fibrillation, benefiting over 28,000 patients with earlier medical intervention.
• The healthcare AI market opportunity is projected to grow to $208.2 billion by 2030, with Biotricity leveraging proprietary cardiac AI combining Google's TensorFlow and AWS infrastructure.
• The company reported a net loss attributable to common stockholders of $11,942,000 for the year ended March 31, 2025, an improvement from $14,928,960 in the prior year.
• Gross profit increased to $10,564,491 for the year ended March 31, 2025, up from $8,356,281 in the prior year, with gross profit percentage improving to 76.6% from 69.3%.
• For the six months ended September 30, 2025, revenue grew 20% year-over-year to $7.8 million, with technology fee revenue increasing by 13.2% to $6.9 million.
• The company reported positive profit from operations for the second consecutive quarter for the six months ended September 30, 2025, at $555,764, compared to a loss of $1,424,518 in the prior year period.
• Adjusted EBITDA for the six months ended September 30, 2025, was $570,677, a significant improvement from a negative $1,305,678 in the prior year period.
• Biotricity was delisted from the Nasdaq Capital Market on August 5, 2024, due to non-compliance with the $35 million Market Value of Listed Securities (MVLS) requirement and now trades on the OTCQB under BTCY.
• The company has an accumulated deficit of $140,968,401 and a working capital deficiency of $18,077,790 as of September 30, 2025, raising substantial doubt about its ability to continue as a going concern.
• Biotricity requires additional capital to support its business plan and anticipated growth, and there is no assurance that such capital will be available on acceptable terms.

Sentiment

Score: 4

Explanation: The company shows strong operational improvements with revenue growth, increased gross margins, and positive operating profit/Adjusted EBITDA in recent periods. However, significant financial risks persist, including substantial accumulated deficit, working capital deficiency, and a going concern opinion from auditors, compounded by the Nasdaq delisting. The continuous need for capital raises and non-compliance with certain debt covenants indicate ongoing financial instability, despite positive operational momentum.

Positives

• Revenue increased by 14.3% to $13.8 million for the year ended March 31, 2025, compared to $12.1 million in the prior fiscal year.
• Gross profit improved significantly to $10.6 million (76.6% gross margin) for the year ended March 31, 2025, from $8.4 million (69.3% gross margin) in the prior year.
• Technology fee revenue, which is largely recurring, increased by 13.2% to $6.9 million for the six months ended September 30, 2025.
• Operating expenses decreased by $4.17 million to $13.0 million for the year ended March 31, 2025, reflecting increased monitoring of spending efficiency.
• The company achieved positive profit from operations of $555,764 for the six months ended September 30, 2025, a significant turnaround from a loss of $1,424,518 in the comparable prior year period.
• Adjusted EBITDA improved to $570,677 for the six months ended September 30, 2025, from a negative $1,305,678 in the prior year, indicating progress towards operating cash-flow break-even.
• Bioheart received recognition as one of TIME's Best Inventions of 2022.
• Received a NIH Grant of $238,703 in March 2023 for AI-enabled real-time monitoring and predictive analytics for stroke due to chronic kidney failure, broadening its technology platform's disease demographic.
• Expanded sales efforts to 33 U.S. states by December 31, 2023, with plans for further expansion.
• Received regulatory approval to operate in Saudi Arabia during the period from April 1 to July 15, 2025.

Negatives

• Incurred a net loss attributable to common stockholders of $11,942,000 for the year ended March 31, 2025, and $1,526,616 for the six months ended September 30, 2025.
• Accumulated deficit reached $140,968,401 as of September 30, 2025.
• Working capital deficiency of $18,077,790 as of September 30, 2025.
• Auditors have indicated substantial doubt about the company's ability to continue as a going concern.
• Delisted from the Nasdaq Capital Market on August 5, 2024, due to failing to meet the $35 million Market Value of Listed Securities (MVLS) requirement, now trading on OTCQB.
• Existing cash deposits of approximately $0.3 million as of September 30, 2025, may not be sufficient to fund operating expenses for the next twelve months.
• Significant levels of indebtedness, approximately $21.1 million as of December 31, 2023, which could lead to defaults and acceleration of debt.
• Not in compliance with certain covenants contained within the Credit Agreement and May 2023 Notes due to a failure to register required shares, potentially leading to default or damages.

Risks

• Existing and future levels of indebtedness could adversely affect financial health, ability to obtain future financing, and ability to react to business changes.
• Auditors have indicated doubt about the ability to continue as a going concern due to recurring losses, negative operating cash flows, and working capital deficiency.
• Requires additional capital to support its business plan and anticipated growth, which may not be available on acceptable terms or at all, leading to potential curtailment of business plans.
• Failure to comply with terms of the Credit Agreement with SWK Funding LLC could result in default and foreclosure on pledged assets, including intellectual property.
• Non-compliance with covenants in the Credit Agreement, May 2023 Notes, and Series B SPA could lead to acceleration of debt or damages.
• Management has broad discretion over the use of offering proceeds, which may not be used effectively or yield favorable returns.
• This is a 'reasonable best efforts' offering with no minimum amount of securities required to be sold, meaning the company may not raise sufficient capital.
• Investors in this offering will experience immediate and substantial dilution due to the offering price being higher than the net tangible book value per share.
• The issuance of additional securities in the future may cause further dilution and depress the market price of common stock.
• Natural disasters, pandemics (like COVID-19), and other uncontrollable events could disrupt operations and supply chains.
• Limited operating history and lack of sustained profitability make it difficult for investors to evaluate future prospects.
• Inability to meet product development and commercialization milestones could delay schedules and deter purchasers.
• Dependence on physicians utilizing its solutions; failure to convince them could decrease revenue.
• Subject to extensive governmental regulations (FDA, Health Canada) for manufacturing, labeling, and marketing, with potential for reclassification of devices (e.g., Class II to Class III) increasing costs and delays.
• Inability of customers to obtain and maintain adequate third-party reimbursement for services using products could materially affect business.
• Product defects could lead to recalls, safety alerts, significant costs, negative publicity, and product liability claims.
• Interruptions in telecommunications systems or data services could impair delivery of cardiac monitoring services and harm reputation.
• Vulnerability of information technology systems to cybersecurity breaches and data leakage risks could result in financial, legal, business, and reputational harm.
• Declining general economic or business conditions, including inflation and financial market instability, may negatively impact the business.
• Global climate change and related regulations could disrupt operations and increase costs.
• Exposure to significant liability claims if unable to obtain adequate insurance or protect against product liability claims.
• Uncertainty of research and development efforts and no assurance of continued commercial success of products.
• Failure to attract and retain qualified personnel, especially key personnel like the CEO, could harm growth strategy.
• Executive and legislative actions related to the Affordable Care Act may adversely affect the business.
• Inability to manufacture products at low prices or maintain regulatory approval of manufacturing facilities could harm business.
• Dependence on a limited number of suppliers for components may prevent timely device delivery.
• Operations in international markets involve inherent uncontrollable risks (macroeconomic conditions, foreign currency, political instability, etc.).
• Highly competitive medical technology industry with rapid technological change and larger competitors.
• Unsuccessful clinical trials could have a material adverse effect on prospects.
• Intellectual property litigation and infringement claims could incur significant expenses or prevent product sales.
• Inability to protect the confidentiality of trade secrets would harm business and competitive position.
• Enforcement of federal and state privacy and security laws (HIPAA) may adversely affect business.
• Potential exposure to federal and state health care fraud and abuse laws and false claims laws.
• Changes in the healthcare industry or tort reform could reduce demand for arrhythmia monitoring solutions.
• If the company fails to comply with Nasdaq's continuing listing standards, its Common Stock could be delisted (already occurred, now on OTCQB).
• Limited existing market for Common Stock and potential for significant number of shares eligible for sale to depress market price.
• Market price of Common Stock has been volatile and can fluctuate substantially.
• The CEO, Waqaas Al-Siddiq, beneficially owns approximately 8.32% of outstanding common stock and can substantially influence the company.
• Failure to maintain effective internal control over financial reporting could cause financial reports to be inaccurate.
• Anti-takeover provisions in charter and bylaws may prevent or frustrate attempts to change the board or management.

Future Outlook

Management anticipates continued revenue growth and improved liquidity through business development and additional equity and debt capitalization. The company plans to continue devoting significant resources to capital expenditures, research and development, operations, marketing, and sales. They expect continued improvement in overall blended gross margin over time due to improved gross margin on technology fees and an evolving revenue mix. Future plans include expanding the use of their technology platform with medical-grade solutions for monitoring implantable cardiac devices, diabetes, sleep apnea, chronic pain, fetal monitoring, and other adjacent healthcare and lifestyle markets. They also anticipate applying for further FDA clearances for advanced ECG analysis software and the Bioflux 2.0 within the next twelve months.

Management Comments

• Management's mission is to innovate and create transformative healthcare products while ensuring financial discipline, to drive margin and revenue growth to deliver value creation for investors.
• Our commitment to innovation means that we harness data intelligently to explore novel avenues for enhancing healthcare outcomes.
• Through research and development, we believe we are redefining medical diagnostics and patient care and innovating new AI-driven solutions.
• We believe our existing cash, along with anticipated near-term financings, will be sufficient to continue to meet our needs for the next twelve months from the filing date of this report.

Industry Context

The company operates in the rapidly growing connected health market, projected to reach $150 billion by 2024 (CAGR of 25%), driven by a shift towards self-management of chronic illnesses. Cardiovascular disease is the number one cost to the healthcare system and the leading cause of death worldwide, creating a significant need for cost-effective diagnostic and management solutions. The global ECG equipment market is projected to grow at a CAGR of 6.5% from 2023 to 2030, with the U.S. market valued at $2.01 billion in 2022. Remote patient monitoring (RPM) is expected to reach $96.67 billion by 2030 (CAGR of 17.6%), with 70 million U.S. patients utilizing it by 2025. The healthcare AI market opportunity is projected to grow to $208.2 billion by 2030. Biotricity aims to differentiate itself by offering an all-in-one cardiac diagnostic and disease management solution, leveraging its proprietary AI model and insourcing business model against competitors who often use outsourced models or less integrated solutions.

Comparison to Industry Standards

• Biotricity's Bioflux and Biocore Pro solutions are positioned against competitors like Philips Biotel (formerly CardioNet), Boston Scientific Preventice (formerly eCardio), ScottCare, Infobionic, and VitalConnect in the Mobile Cardiac Outpatient Monitoring (COM) market.
• Unlike many competitors (e.g., Philips Biotel, Boston Scientific Preventice, VitalConnect) that employ an outsourced business model for COM diagnostics, Biotricity uses an insourcing model, empowering physicians directly and charging technology service fees.
• Biotricity's Biocore solution is technologically superior as a one-piece solution with 3 channels of ECG and integrated cellular connectivity, compared to existing COM solutions that are often two-piece with 2 channels or lack connectivity.
• In the Holter/Extended Holter market, Biotricity's Biocore competes with iRhythm Technologies (Zio patch), BardyDx, and VitalConnect. Biocore offers 3-channel connectivity, reducing diagnosis time from 2 weeks to 3 days or less, which is a significant advantage over 1-channel, non-connected patches.
• In cardiac disease management, Biotricity's Bioheart and Biocare offer the first cardiac-tailored continuous heart rhythm monitoring solution, differentiating from generic platforms like Optimize Health or hypertension-focused programs like HelloHeart, which primarily target diabetes, obesity, and hypertension.
• The company's proprietary cardiac AI model, combining Google's TensorFlow and AWS infrastructure, is a competitive advantage in the growing healthcare AI market, enabling support for more patients and critical data identification.

Management Changes

Corporate Governance

Legal Proceedings

• There are no legal proceedings pending or threatened against the company as of March 31, 2025, and September 30, 2025.

Related Party Transactions

• Trade and other payables and accrued liabilities included $417,085 as of September 30, 2025, and $373,744 as of March 31, 2025, due to a shareholder who is also a director and executive of the company.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future equity offerings due to the company's capital needs.
• Shareholders are exposed to high investment risk due to recurring losses, accumulated deficit, and going concern doubt.
• The Nasdaq delisting impacts liquidity and market perception for shareholders, potentially leading to lower prices and larger bid-ask spreads.
• Employees benefit from stock-based compensation plans (2016 and 2023 Equity Incentive Plans, ESPP) as incentives.
• Customers benefit from continued product development, FDA clearances, and expansion of cardiac monitoring and disease management solutions, potentially leading to improved patient care and cost savings.
• Creditors face risk due to the company's high indebtedness and non-compliance with certain debt covenants, which could lead to acceleration of debt obligations and actions against pledged assets.

Next Steps

• Expand sales force to address new markets and achieve sales penetration in currently served markets.
• Apply for further FDA clearances for advanced ECG analysis software and the Bioflux 2.0 within the next twelve months.
• Continue developing AI technology in remote cardiac care to enhance disease profiling, improve patient management, and revolutionize disease prevention.
• Seek additional debt or equity capital to fund ongoing operating expenses, protect intellectual property, develop new lines of business, and enhance operating infrastructure.
• Present a plan to the Nasdaq Hearings Panel to regain compliance with listing requirements (though delisting has occurred, appeal is pending).
• Continue to identify and develop other efficient, automated, low-cost manufacturing capabilities and options.

Key Dates

Recommendation

While Biotricity Inc. demonstrates strong operational progress with significant revenue growth, improved gross margins, and positive operating profit/Adjusted EBITDA in recent periods, the company faces substantial financial challenges. The recurring losses, accumulated deficit, working capital deficiency, and the auditors' going concern opinion highlight significant financial instability. The Nasdaq delisting further impacts market perception and liquidity. However, the company's continued innovation in cardiac monitoring, FDA clearances, AI development, and expansion into new markets present a compelling growth narrative. For a seasoned investor, the operational improvements and market potential suggest that the company is making strides, but the severe financial risks and ongoing need for capital necessitate a cautious approach. A 'hold' recommendation acknowledges the positive operational momentum while emphasizing the high-risk profile and the need for continued monitoring of financial stability and successful capital raises.

Keywords

Medical Technology, Cardiac Monitoring, Remote Patient Monitoring, AI Healthcare, Biometric Data, FDA Clearance, Chronic Disease Management, Digital Health, Wearable Technology, S-1 Filing, Biotricity